Welcome to
The Evidence Network
microsite

Looking to discover more about Stelara® (ustekinumab) in the management of inflammatory bowel disease (IBD)?
Our e-learning modules offer a quick, interactive way to get up to speed with the clinical trial results and real-world evidence.

Stelara® (ustekinumab)

Stelara® is indicated for the treatment of adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.1

Stelara® is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.1

Stelara® has over 10 years' clinical experience across four immune-mediated inflammatory disease indications.1 A fully human monoclonal antibody, Stelara® is the only approved treatment for CD and UC that targets both IL-12 and IL-23.1,2

Click here for full Stelara® prescribing information

The Evidence Network

The Evidence Network is a programme designed to facilitate the sharing of good practice and to provide insights on the clinical trial results and real-world evidence for Stelara® and other biologics in IBD, while considering what this means for everyday clinical practice.

The syllabus for this programme has been carefully developed in partnership with a steering committee of gastroenterology experts which has been set up and funded by Janssen. This syllabus is not only used to inform a series of live workshops and webinars held throughout the UK, but has also been used to develop a range of learning resources to support The Evidence Network programme, including a series of interactive e-learning modules, which are available on this site.

References

1. Stelara® SmPC. Available at: www.medicines.org.uk/emc [accessed July 2021].2. Wong U, Cross RK. Exp Op Invest Drugs. 2019;28:473-9.

Abbreviations

CD: Crohn's disease; IBD: inflammatory bowel disease; IL: interleukin; TNF: tumour necrosis factor; UC: ulcerative colitis

Adverse events should be reported. Reporting forms and information can be found at
https://yellowcard.mhra.gov.uk
or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Janssen-Cilag Limited on 01494 567 447 or at .